Table 1.
Patient demographics and disease characteristics (N = 295)
| Variable | Statistic | Result |
|---|---|---|
| Age, years | Median (range) | 63 (49–75) |
| ≤ 60 | 94 (31.9%) | |
| > 60 to 70 | 169 (57.3%) | |
| > 70 | 32 (10.8%) | |
| T-stage | T1c | 44 (14.9%) |
| T2 | 251 (85.1%) | |
| Nuclear grade | 1 | 195 (66.1%) |
| 2 | 59 (20.0%) | |
| 3 | 27 (9.2%) | |
| Missing | 14 (4.7%) | |
| Tumor size, mm | Median (range) | 25 (20–65) |
| Ki-67 by IHC, % | Median (range) | 16.2 (0.0, 82.5) |
| Ki-67 category | < 10% | 86 (29.2%) |
| 10–30% | 123 (41.7%) | |
| > 30% | 61 (20.7%) | |
| Missing | 25 (8.5%) | |
| ESR1 by RT-PCR | Median (range) | 11.7 (5.7–14.6) |
| Mean (st dev) | 11.5 (1.3) | |
| ER category, determined by RT-PCR | Positive (≥ 6.5) | 293 (99.3%) |
| Negative (< 6.5) | 2 (< 1.0%) | |
| PGR by RT-PCR | Median (range) | 7.1 (2.6–11.4) |
| Mean (st dev) | 6.7 (2.0) | |
| PgR category, determined by RT-PCR | Positive (≥ 5.5) | 211 (71.5%) |
| Negative (< 5.5) | 84 (28.5%) | |
| HER2 category, determined by RT-PCR | Negative (< 10.7) | 235 (79.7%) |
| Positive (≥ 11.5) | 9 (3.1%) | |
| Equivocal (10.7 to < 11.5) | 51 (17.3%) | |
| Recurrence Score result | Median (range) | 17 (0–68) |
ER estrogen receptor, HER2 human epidermal growth factor receptor 2, IHC immunohistochemistry, PgR progesterone receptor, RT-PCR reverse transcription-polymerase chain reaction, st dev standard deviation